The South Dakota Tuberculosis (TB) Control Program recommends diagnosis and treatment of patients with TB disease and latent TB infection per the recommendations from the Centers for Disease Control and Prevention (CDC) and the American Thoracic Society. These guidelines may be obtained by contacting the TB Control Program at 605-773-3737 or from the CDC website.
- Treatment of Drug-Susceptible TB
- Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis
- Frequently Asked Questions (FAQs): A 4-Month Regimen to Treatment Pulmonary Tuberculosis: Isoniazid, Rifapentine, Moxifloxacin, and Pyrazinamide (HPMZ)
- A 4-Month Regimen to Treat Pulmonary Tuberculosis: Isoniazid, Rifapentine, Moxifloxacin, and Pyrazinamide (HPMZ)
- Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis Infection
- Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
- Tuberculosis Screening, Testing and Treatment of US Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019
- Targeted Tuberculin Testing and Treatment of Latent Tuberculin Infection
- Controlling Tuberculosis in the United States
- Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis
- Updated Guidelines for Using the InterFERON Gamma Release Assays to Detect Mycobacterium Tuberculosis Infection - US, 2010
- Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-care Settings
- Prevention and Control of Tuberculosis in Correctional and Detention Facilities
- Clinical Guidelines (CDC)
- Updated Treatment Recommendations for 3HP
- Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor-Alpha